uniQure Faces Securities Lawsuit Over Huntington's Study Design Misrepresentation

Rosen Law Firm is actively notifying investors in uniQure N.V. ($QURE) about a pending securities class action lawsuit, with a critical deadline of April 13, 2026 for investors to serve as lead plaintiff. The lawsuit centers on allegations that the NASDAQ-listed gene therapy company made material misrepresentations and omissions regarding its Pivotal Study for Huntington's Disease treatment between September 24, 2025 and October 31, 2025, a period that proved pivotal for the biotech firm's stock valuation and investor confidence.

The Core Allegations

The securities lawsuit alleges two significant breaches of disclosure obligations by uniQure:

• Study Design Misrepresentation: The company allegedly misrepresented that its Pivotal Study design for the Huntington's Disease treatment had received full FDA approval, when in fact this critical regulatory endorsement was not complete at the time of public statements
• Timeline Downplaying: uniQure purportedly downplayed the likelihood and severity of delays to its Biologics License Application (BLA) timeline, misleading investors about the realistic probability of regulatory setbacks

For gene therapy companies like uniQure, study design approval and BLA timelines represent fundamental milestones that directly impact stock valuations and investor decision-making. The alleged misstatements occurred during a concentrated two-month window, suggesting potential coordination of public communications that may not have fully reflected regulatory realities.

The window for investor action remains narrow. Shareholders who purchased QURE shares during this period and suffered losses have until April 13, 2026 to file as lead plaintiff—a deadline that underscores the urgency of the matter for affected investors. Institutional investors and those holding significant positions are typically the first to pursue lead plaintiff status, given the legal resources and documentation required.

Market Context and Industry Backdrop

The allegations against uniQure occur within a challenging period for the gene therapy sector. Gene therapy stocks have faced heightened regulatory scrutiny and investor skepticism following multiple clinical trial setbacks and manufacturing complications across the industry. Companies pursuing rare disease treatments, particularly neurological conditions like Huntington's Disease, operate under particularly stringent FDA oversight given the vulnerable patient populations involved.

uniQure's Huntington's Disease program represents a potentially transformative asset for the company, as effective treatments for this degenerative neurological condition remain extremely limited. The stakes surrounding study design and regulatory approval are therefore exceptionally high—both for the company's commercial prospects and for patients awaiting therapeutic options. Any miscommunication or downplaying of regulatory challenges could represent a material breach of the company's disclosure obligations to shareholders.

The biotech sector has witnessed increasing litigation risk around regulatory representations in recent years. The SEC and Department of Justice have intensified scrutiny of life sciences companies' public statements regarding clinical trial progress and regulatory timelines, recognizing that investors rely heavily on these forward-looking assertions when making investment decisions.

Investor Implications and Legal Considerations

For QURE shareholders, this lawsuit carries significant implications:

• Stock Price Impact: Securities class actions typically indicate prior stock price declines following disclosure of the alleged misstatements. Investors who purchased during the September-October 2025 window and subsequently sold at lower prices after corrections become plaintiffs
• Recovery Potential: Successful class actions in biotech cases have yielded substantial settlements, though outcomes depend on demonstrating scienter (intent to deceive) and causation between alleged misstatements and stock losses
• Lead Plaintiff Status: The most active investors or institutional shareholders may secure lead plaintiff positions, which can influence settlement negotiations and legal strategy
• Company Liability: A successful verdict or substantial settlement could materially impact uniQure's financial position and access to capital, particularly critical for a clinical-stage gene therapy company

The choice of Rosen Law Firm to lead investor outreach suggests the law firm has identified compelling evidence of securities violations. Rosen, a prominent securities litigation firm, typically pursues cases where documentary evidence supports claims of material misrepresentation—such as internal communications contradicting public statements or regulatory correspondence indicating fuller knowledge of approval status among company leadership.

Investors should consult with qualified securities counsel before the April 13, 2026 deadline. Participation in securities class actions does not require special action beyond retention of purchase documentation and communication with class counsel; however, investors who wish to serve as lead plaintiff must affirmatively apply and demonstrate their suitability before the deadline.

Looking Forward

The securities class action against uniQure highlights the critical importance of precise disclosure practices in the biotech industry, where regulatory approval represents the primary value driver for clinical-stage companies. As the gene therapy sector matures and regulatory pathways become increasingly complex, companies face mounting legal exposure when public statements diverge from internal regulatory understandings or project unrealistic timelines.

For QURE shareholders, the April deadline represents an important opportunity to protect their interests through potential recovery mechanisms. The ultimate resolution—whether through settlement or verdict—will likely influence how uniQure and peer companies communicate regulatory matters to investors going forward, potentially benefiting future shareholders through enhanced disclosure practices.

Investors holding uniQure shares during the relevant period should immediately consult with experienced securities attorneys to understand their rights and options under the class action framework.